vTv Therapeutics (NASDAQ:VTVT) Earns Buy Rating from BTIG Research

vTv Therapeutics (NASDAQ:VTVT – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a research note issued on Wednesday, Benzinga reports. They presently have a $57.00 price target on the biotechnology company’s stock. BTIG Research’s target price indicates a potential upside of 104.74% from the company’s current price.

Several other equities analysts have also recently issued reports on the company. Wall Street Zen raised vTv Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 3rd. Rodman & Renshaw assumed coverage on vTv Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $67.00 target price on the stock. HC Wainwright reduced their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Weiss Ratings cut vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, Lifesci Capital raised vTv Therapeutics to a “strong-buy” rating in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.83.

Get vTv Therapeutics alerts:

Check Out Our Latest Analysis on vTv Therapeutics

vTv Therapeutics Price Performance

VTVT traded down $0.39 during trading on Wednesday, reaching $27.84. 5,449 shares of the company’s stock were exchanged, compared to its average volume of 53,446. vTv Therapeutics has a 1 year low of $19.50 and a 1 year high of $44.00. The stock has a market capitalization of $109.69 million, a P/E ratio of -26.31 and a beta of 0.21. The company’s fifty day simple moving average is $31.90 and its 200-day simple moving average is $33.55.

vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.08). Equities analysts forecast that vTv Therapeutics will post -2.35 EPS for the current year.

vTv Therapeutics Company Profile

(Get Free Report)

vTv Therapeutics, Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered small-molecule medicines for chronic diseases. The company’s research has primarily addressed metabolic and neurological disorders, including diabetes and Alzheimer’s disease.

vTv’s development portfolio has included cadisegliatin (also known as TTP399), an oral, liver-selective glucokinase activator being studied as a potential treatment for type 1 diabetes, and azeliragon, an investigational drug designed to inhibit the receptor for advanced glycation end products (RAGE) in Alzheimer’s disease.

Featured Articles

• Five stocks we like better than vTv Therapeutics
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know
• How a Hurricane Could Help Some Refineries—and Hurt Others
• Intel Bets on Cheaper AI as Foundry Losses Mount
• Don’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could Deepen

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.